Literature DB >> 1691173

Isolation of a lipopolysaccharide (LPS)-resistant mutant, with defective LPS binding, of cultured macrophage-like cells.

S Hara-Kuge1, F Amano, M Nishijima, Y Akamatsu.   

Abstract

Lipopolysaccharide (LPS)-resistant mutants which did not respond to LPS were isolated from a macrophage-like mouse cell line, J774.1. Unlike the parental J774.1 cells, these mutants grew even in LPS added medium as well as in normal growth medium without any morphological changes. Assay of 125I-LPS binding to the cell monolayers revealed that one of these LPS-resistant mutants (LR-9) was strikingly defective in LPS-binding activity. Scatchard plot showed that LR-9 cells lacked the high affinity binding sites which were present in J774.1. The high affinity binding was inhibited by addition of excess unlabeled LPS, lipid A, lipid IVA (tetraacyl-beta(1'-6)-linked D-glucosamine disaccharide-1,4'-bisphosphate), and lipid X (2,3-diacylglucosamine 1-phosphate) and sensitive to proteinase K. LPS enhanced O2- generation and the release of arachidonic acid in J774.1 cells but not in LR-9 cells. Other stimulants such as zymosan and 12-O-tetradecanoylphorbol 13-acetate, however, induced the release of arachidonic acid in LR-9 cells as well as in J774.1 cells. LPS-photocross-linked assay allowed the identification of 65- and 55-kDa LPS-binding proteins in the membrane fraction of J774.1 cells. Both of the bands were not detectable in that of LR-9 cells and disappeared by competing with unlabeled LPS or lipid X. These results show that one or both of the two LPS-binding proteins might relate to the specific membrane receptor for LPS.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691173

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Involvement of diacylglycerol production in activation of nuclear factor kappaB by a CD14-mediated lipopolysaccharide stimulus.

Authors:  H Yamamoto; K Hanada; M Nishijima
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Identification and characterization of lipopolysaccharide-binding proteins on human peripheral blood cell populations.

Authors:  J L Halling; D R Hamill; M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

3.  A lipopolysaccharide (LPS)-resistant mutant isolated from a macrophagelike cell line, J774.1, exhibits an altered activated-macrophage phenotype in response to LPS.

Authors:  F Amano; Y Akamatsu
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

4.  Role of CD14 molecules in internalization of Actinobacillus actinomycetemcomitans by macrophages and subsequent induction of apoptosis.

Authors:  M Muro; T Koseki; S Akifusa; S Kato; Y Kowashi; Y Ohsaki; K Yamato; M Nishijima; T Nishihara
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

5.  Micrococcus luteus teichuronic acids activate human and murine monocytic cells in a CD14- and toll-like receptor 4-dependent manner.

Authors:  S Yang; S Sugawara; T Monodane; M Nishijima; Y Adachi; S Akashi; K Miyake; S Hase; H Takada
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Evidence that lipopolysaccharide and pertussis toxin bind to different domains on the same p73 receptor on murine splenocytes.

Authors:  M G Lei; D C Morrison
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

Review 7.  The role of CD14 and lipopolysaccharide-binding protein (LBP) in the activation of different cell types by endotoxin.

Authors:  R R Schumann; E T Rietschel; H Loppnow
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

Review 8.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

9.  Mechanisms of nonopsonic phagocytosis of Pseudomonas aeruginosa.

Authors:  T Mork; R E Hancock
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.